Shattuck Labs is a clinical-stage biotechnology company pioneering the development of a novel class of bi-functional fusion proteins for the treatment of cancer and autoimmune disease. Shattuck’s Agonist Redirected Checkpoint (ARC) technology represents the next evolutionary step in cancer therapy by endowing one molecule with multiple, synergistic functions.
IPO in October 2020 (NASDAQ: STTK)
